source
- Scynexis secures $214 million BARDA contract to advance oral and IV antifungal SCY-247BARDA awarded Scynexis a $214 million contract to develop a treatment for invasive fungal infections, including an upfront payment of about $18.5 million. The funding will support moving SCY-247,…
- Tolerance Bio signs up to $560M deal for anti-IL-33 drug from TanabeTolerance Bio has licensed the rights to an anti‑IL‑33 monoclonal antibody from Mitsubishi Tanabe Pharma for use outside Japan. The antibody, previously known as MT‑2990 and to be renamed TLB‑33, w…